• Mutation; HGNC; HGNC:6844; MAP2K4; Simple; p.Lys309Asn (c.927G>C); Zygosity=Unspecified (PubMed=9331070).
  
• Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Arg173Pro (c.518G>C); ClinVar=VCV000185195; Zygosity=Heterozygous (Cosmic-CLP=908441; DepMap=ACH-001578).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Val272Cysfs*73 (c.814delG); Zygosity=Homozygous (Cosmic-CLP=908441; DepMap=ACH-001578).
  

PubMed=2842544
Teshima S.-i., Shimosato Y., Hirohashi S., Tome Y., Hayashi I., Kanazawa H., Kakizoe T.
Four new human germ cell tumor cell lines.
Lab. Invest. 59:328-336(1988)

PubMed=9331070
Teng D.H.-F., Perry W.L. 3rd, Hogan J.K., Baumgard M.L., Bell R., Berry S., Davis T., Frank D., Frye C., Hattier T., Hu R., Jammulapati S., Janecki T., Leavitt A., Mitchell J.T., Pero R., Sexton D., Schroeder M., Su P.-H., Swedlund B., Kyriakis J.M., Avruch J., Bartel P., Wong A.K.C., Oliphant A., Thomas A., Skolnick M.H., Tavtigian S.V.
Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor.
Cancer Res. 57:4177-4182(1997)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=24812411; DOI=10.1158/1078-0432.CCR-13-2868
Feldman D.R., Iyer G., Van Alstine L., Patil S., Al-Ahmadie H., Reuter V.E., Bosl G.J., Chaganti R.S.K., Solit D.B.
Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors.
Clin. Cancer Res. 20:3712-3720(2014)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31500094; DOI=10.3390/cancers11091316; PMCID=PMC6769617
Bakardjieva-Mihaylova V., Skvarova Kramarzova K., Slamova M., Svaton M., Rejlova K., Zaliova M., Dobiasova A., Fiser K., Stuchly J., Grega M., Rosova B., Zachoval R., Klezl P., Eis V., Kindlova E., Buchler T., Trka J., Boublikova L.
Molecular basis of cisplatin resistance in testicular germ cell tumors.
Cancers (Basel) 11:1316.1-1316.18(2019)

PubMed=35084545; DOI=10.1007/s00345-022-03936-1; PMCID=PMC8921118
Fichtner A., Bohnenberger H., Elakad O., Richter A., Lenz C., Oing C., Strobel P., Kueffer S., Nettersheim D., Bremmer F.
Proteomic profiling of cisplatin-resistant and cisplatin-sensitive germ cell tumour cell lines using quantitative mass spectrometry.
World J. Urol. 40:373-383(2022)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)